MSDC 0160

MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease^[1][2]. In Vitro: MSDC 0160 (Mitoglitazone; 1-50 μM; for 24 hours) significantly decreases phosphorylation of mTOR at 20 and 50 μM^[1].
MSDC 0160 acts as insulin sensitizers without activating PPARγ^[1].
MSDC 0160 (10 μM; pretreatment 1 hour) prevents the MPP⁺ (10 μM)-induced loss of both tyrosine hydroxylase (TH)-immunoreactive differentiated Lund human mesencephalic (LUHMES) cells^[1].
MSDC 0160 (10 or 100 μM) prevents the loss of GFP-fluorescent dopaminergic neurons induced by MPP⁺ (0.75 mM) in nematodes^[1].
MSDC 0160 (10-20 μM) in conbination with IGF-1 prevents the loss of insulin content and maintains insulin secretion^[1].
MSDC 0160 (1-50 μM) treatment maintains human β-cell phenotype^[2]. In Vivo: MSDC 0160 (Mitoglitazone; 30 mg/kg; oral gavage; daily; for 7 days) improves locomotor behavior, increases survival of nigral dopaminergic neurons, boosts striatal dopamine levels, and reduces neuroinflammation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice^[2].